Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.06 AUD
Change Today -0.002 / -3.28%
Volume 1.3M
As of 2:10 AM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

prima biomed ltd (PRR) Snapshot

Open
A$0.06
Previous Close
A$0.06
Day High
A$0.06
Day Low
A$0.06
52 Week High
05/21/15 - A$0.19
52 Week Low
05/6/15 - A$0.02
Market Cap
103.3M
Average Volume 10 Days
4.2M
EPS TTM
A$-0.01
Shares Outstanding
1.8B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PRIMA BIOMED LTD (PRR)

Related News

No related news articles were found.

prima biomed ltd (PRR) Related Businessweek News

No Related Businessweek News Found

prima biomed ltd (PRR) Details

Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product currently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.

31 Employees
Last Reported Date: 08/27/14

prima biomed ltd (PRR) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: A$250.2K
Chief Technical Officer
Total Annual Compensation: A$325.6K
General Counsel and Company Secretary
Total Annual Compensation: A$160.0K
Compensation as of Fiscal Year 2014.

prima biomed ltd (PRR) Key Developments

Prima BioMed To Maintain NASDAQ Listing

Prima BioMed Ltd announces that, further to the announcement made on 29 December 2014, it has received a notice, dated 3 June 2015 from the Listing Qualifications Department of The NASDAQ Stock Market, indicating that, for the 10 consecutive business days from 19 May 2015 to 2 June 2015, the closing bid price of the Company's American Depositary Shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1) and the Company's shares will remain listed on The NASDAQ Global Market.

Prima Biomed Ltd. Presents at 5th LD Micro Invitational Conference, Jun-01-2015

Prima Biomed Ltd. Presents at 5th LD Micro Invitational Conference, Jun-01-2015 . Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States.

Prima Biomed Ltd. Reaches Agreement with Database Integrations Inc. to Commercialise iCAN, Software Platform

On May 25, 2015, Prima Biomed Ltd. announced that it has reached an agreement with Database Integrations Inc. (DBI) for the two companies to commercialise iCAN, the software platform that powers Prima's CVac cellular therapy, for use in other cellular therapies worldwide. iCAN, which was designed by DBI to Prima's specifications and commissioned in 2011, handles, in a scalable architecture and with a high level of automation, all the electronic records and electronic signatures associated with labelling, manufacturing operations, distribution, logistics, communications and scheduling for immuno-cellular therapies like CVac. With iCAN having significantly contributed to making CVac an efficient and relatively low cost cellular therapy in the years since 2011, Prima and DBI believe that other developers of cellular therapies will benefit from iCAN with their products. Under the Agreement being announced the two companies will work together to seek sub-licensees for that system. It is envisaged that Prima will earn a percentage of the revenues that Database Integrations earns from new sub-licensees.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRR:AU A$0.06 AUD -0.002

PRR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRR.
View Industry Companies
 

Industry Analysis

PRR

Industry Average

Valuation PRR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.7x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 61.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRIMA BIOMED LTD, please visit www.primabiomed.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.